Wegovy (semaglutide) is approved by NMPA (China) for long-term weight management for overweight and obese people
Novo Nordisk’s weight-loss drug Wegovy has been approved for sale in China, opening the door to a huge market in which obesity rates have more than doubled among adults in the past two decades
The Danish pharmaceutical company said that Wegovy “has been approved in China for long-term weight management” for overweight and obese people. It did not say when the product would launch and declined to share details on pricing or the volume of Wegovy it would supply to the region.
The popularity of the drugs has helped make Novo Nordisk Europe’s most valuable company, with a market valuation of $630.5bn, even as it has struggled to meet huge demand for its products, at times prioritising the supply of the drugs to existing patients rather than new users.
Wegovy, contains the active ingredient semaglutide, has been approved in China for long-term weight management for overweight and obese people.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.